This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ciaraldi, T. P. Articles by Yen, S. S. C. Search for Related Content PubMed PubMed Citation Articles by Ciaraldi, T. P. Articles by Yen, S. S. C.

Cellular Insulin Resistance in Adipocytes from Obese Polycystic Ovary Syndrome Subjects Involves Adenosine Modulation of Insulin Sensitivity¹

Department of Medicine, Division of Endocrinology/Metabolism (T.P.C., M.G.H., R.O.-F., J.M.O.), and the Department of Reproductive Medicine (A.J.M., S.C.Y.), University of California-San Diego, La Jolla, California 92093

Address all correspondence and requests for reprints to: Dr. Theodore P. Ciaraldi, Division of Endocrinology (0673), University of California-San Diego, La Jolla, California 92093. E-mail tciaraldi{at}ucsd.edu

Cellular insulin resistance in polycystic ovary syndrome (PCOS) has been shown to involve a novel postbinding defect in insulin signal transduction. To find possible mechanisms for this defect, adipocytes were isolated from age- and weight-matched obese normal cycling (NC) and PCOS subjects. Insulin sensitivity for glucose transport stimulation was impaired in PCOS adipocytes (EC₅₀ = 290 ± 42 pmol/L) compared to that in NC cells (93 ± 14; P < 0.005). The lipolytic responses to isoproterenol as well as maximal suppression by insulin were similar in NC and PCOS adipocytes. However, PCOS cells were less sensitive to the antilipolytic effect of insulin (EC₅₀ = 115 ± 33 pmol/L) compared to NC cells (42 ± 8; P < 0.01). Treatment of adipocytes from NC subjects with the adenosine receptor agonist N⁶-phenylisopropyl adenosine had no effect on either insulin responsiveness or sensitivity for glucose transport stimulation. However, N⁶-phenylisopropyl adenosine treatment was able to normalize insulin sensitivity in PCOS cells (EC₅₀ = 285 ± 47 vs. 70 ± 15 pmol/L, before and after treatment; P < 0.05). In conclusion, our results suggest that insulin resistance in PCOS, as accessed in the adipocyte, occurs at an early step in insulin signaling that is common for glucose transport and lipolysis. In addition, this insulin resistance involves an impairment of the system by which adenosine acts to modulate insulin signal transduction.

This article has been cited by other articles:

				M. Corton, J. I. Botella-Carretero, A. Benguria, G. Villuendas, A. Zaballos, J. L. San Millan, H. F. Escobar-Morreale, and B. Peral Differential Gene Expression Profile in Omental Adipose Tissue in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 328 - 337. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Third Annual World Congress on the Insulin Resistance Syndrome: Associated conditions. Diabetes Care, September 1, 2006; 29(9): 2165 - 2174. [Full Text] [PDF]

				K.-M. Seow, C.-C. Juan, L.-Y. Wu, Y.-P. Hsu, W.-M. Yang, Y.-L. Tsai, J.-L. Hwang, and L.-T. Ho Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance Hum. Reprod., January 1, 2004; 19(1): 48 - 53. [Abstract] [Full Text] [PDF]

				F. Orio Jr., G. Matarese, S. Di Biase, S. Palomba, D. Labella, V. Sanna, S. Savastano, F. Zullo, A. Colao, and G. Lombardi Exon 6 and 2 Peroxisome Proliferator-Activated Receptor-{gamma} Polymorphisms in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5887 - 5892. [Abstract] [Full Text] [PDF]

				V. De Leo, A. la Marca, and F. Petraglia Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome Endocr. Rev., October 1, 2003; 24(5): 633 - 667. [Abstract] [Full Text] [PDF]

				D. Romualdi, M. Guido, M. Ciampelli, M. Giuliani, F. Leoni, C. Perri, and A. Lanzone Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome Hum. Reprod., June 1, 2003; 18(6): 1210 - 1218. [Abstract] [Full Text] [PDF]

				G. Faulds, M. Ryden, I. Ek, H. Wahrenberg, and P. Arner Mechanisms behind Lipolytic Catecholamine Resistance of Subcutaneous Fat Cells in the Polycystic Ovarian Syndrome J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2269 - 2273. [Abstract] [Full Text] [PDF]

				R. Azziz Polycystic Ovary Syndrome, Insulin Resistance, and Molecular Defects of Insulin Signaling J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4085 - 4087. [Full Text] [PDF]

				P. J.Marsden, A. P. Murdoch, and R. Taylor Adipocyte insulin action following ovulation in polycystic ovarian syndrome Hum. Reprod., September 1, 1999; 14(9): 2216 - 2222. [Abstract] [Full Text] [PDF]

				L. Poretsky, N. A. Cataldo, Z. Rosenwaks, and L. C. Giudice The Insulin-Related Ovarian Regulatory System in Health and Disease Endocr. Rev., August 1, 1999; 20(4): 535 - 582. [Abstract] [Full Text] [PDF]

				J. F. Strauss III and A. Dunaif Molecular Mysteries of Polycystic Ovary Syndrome Mol. Endocrinol., June 1, 1999; 13(6): 800 - 805. [Full Text]

				A. Dunaif Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis Endocr. Rev., December 1, 1997; 18(6): 774 - 800. [Abstract] [Full Text]